0.69
+0.0534(+8.33%)
Currency In USD
| Previous Close | 0.64 |
| Open | 0.66 |
| Day High | 0.78 |
| Day Low | 0.64 |
| 52-Week High | 34.92 |
| 52-Week Low | 0.61 |
| Volume | 313,012 |
| Average Volume | 1.44M |
| Market Cap | 2.36M |
| PE | -0.04 |
| EPS | -19.67 |
| Moving Average 50 Days | 1.1 |
| Moving Average 200 Days | 3.33 |
| Change | 0.05 |
If you invested $1000 in AIM ImmunoTech Inc. (AIM) 10 years ago, it would be worth $8.77 as of March 08, 2026 at a share price of $0.694. Whereas If you bought $1000 worth of AIM ImmunoTech Inc. (AIM) shares 5 years ago, it would be worth $345.47 as of March 08, 2026 at a share price of $0.694.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
AIM ImmunoTech Announces Closing of its Rights Offering
GlobeNewswire Inc.
Yesterday at 12:00 AM GMT
OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod),
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million
GlobeNewswire Inc.
Mar 04, 2026 2:00 PM GMT
OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod),
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
GlobeNewswire Inc.
Mar 02, 2026 2:00 PM GMT
OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business of Thermo Fisher Scientific to design AIM’s anticipated Phase 3